TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding RNA-based compound designed to provide a ...
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Sept. 18, 2023 /PRNewswire/ - ESSA Pharma Inc. (EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results